Early improvements in skin clearance were observed, with significant differences in vIGA-AD response rates as early as week 1 and maintained through week 8 in children with or without atopic ...
Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated:59% risk reduction in ACM in the ...
Discover the highest-paying, most in-demand AI jobs, newly created with entry points for professionals seeking to pivot from fields like education, law and medicine.
Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in ...
You keep your trusty reusable bottle filled with only clear, delicious water. Do you still need to wash it? Experts say reusable bottles get grubby no matter what liquid they're filled with, and it's ...
Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE ...
Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented positive clinical data from a ...
Vertex Pharmaceuticals Incorporated today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the ...
Efficacy and safety of subcutaneous self-administered gefurulimab in generalized myasthenia gravis: topline results from a ...
Cynata Therapeutics Limited ( OTCPK:CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation November 5, 2025 8:30 PM EST ...
Medpage Today on MSN
Meta-Analyses Argue for Broader Use of SGLT2 Inhibitors in Chronic Kidney Disease
The first meta-analysis analyzed 70,361 participants from 10 randomized trials, and found those allocated to receive an SGLT2 ...
Ionis Pharmaceuticals, Inc. today announced positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). The studies met the primary ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果